Lv11
48 积分 2021-01-06 加入
Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study
1小时前
求助中
To degrade or not to degrade: mechanisms and significance of endocytic recycling
10天前
已完结
Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer
3个月前
已完结
Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer
3个月前
已完结
Tissue factor in atherosclerosis and atherothrombosis
3个月前
已完结
Tissue factor overexpression in triple-negative breast cancer promotes immune evasion by impeding T-cell infiltration and effector function
3个月前
已完结
Alternatively spliced human tissue factor: a circulating, soluble, thrombogenic protein
3个月前
已关闭
A Phase 1 study of the anti-tissue factor antibody-drug conjugate XB002 in patients with advanced solid tumors (JEWEL-101): initial results from the dose-escalation stage
4个月前
已完结
Phase 1 Study of the Tissue Factor–Targeting Antibody-Drug Conjugate XB002 in Patients with Advanced Solid Tumors (JEWEL-101): Design of Expansion Cohorts for Squamous Cell Carcinoma of the Head and Neck
4个月前
已完结
Recent advancements in the B7/CD28 immune checkpoint families: new biology and clinical therapeutic strategies
4个月前
已完结
皖公网安备34019202002308
